Fibrocell Science (FCSC) Inactive 10-K2018 FY Annual report

Filed: 27 Mar 19, 4:37pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: Adipose, Africa, American, autoantibody, belief, Biotech, Celution, circulating, Cleveland, comfort, Condensed, Congressional, contacted, dialogue, diffuse, dominant, donut, draft, durability, durable, EB, EBMRF, EBRP, ETASU, exacerbate, exploratory, exploring, fibril, filer, forum, GMP, Habeo, hematology, hole, IEM, immunoelectron, interval, Israel, Krystal, left, line, magnitude, maximize, motivate, movement, nonemployee, notable, Ohio, OOPD, phenomenon, Pittsburgh, preclinical, prominent, Raynaud, reconsent, repeal, retroviral, robust, role, sensitivity, Singapore, sooner, STAR, step, straight, subpopulation, substituted, substitution, truthful, unclear, unhealed, verbal, version, widespread

Removed: achievability, achieved, amortizing, assisting, assured, biologically, calling, collaborative, collectability, committed, complicating, concept, conditioned, customer, DC, declaration, delisted, deliverable, determinable, device, effort, electronically, enrolled, establishment, expended, feasibility, FIFO, guide, harvest, improving, inconclusive, indexed, input, inventory, length, linear, Marino, media, Michael, NE, oral, outlined, persuasive, physiologic, plausibility, PPACA, practicable, preempted, proof, prorata, prospectively, rationale, recognizing, rejected, replicated, Room, route, shipped, shipping, Street, Washington

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

FCSC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, I, John M. Maslowski, Chief Executive Officer of Fibrocell Science, Inc. (the "Company"), hereby certify that, to the best of my knowledge:

i.the Annual Report on Form 10-K of the Company for the year ended December 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

ii. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 27, 2019



By:	/s/ John M. Maslowski
	John M. Maslowski
	President and Chief Executive Officer
	(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
	Fibrocell Science, Inc.

A signed original of this written statement required by Section 906 has been provided to Fibrocell Science, Inc. and will be retained by Fibrocell Science, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.